Novo Nordisk's trial to treat Alzheimer's with its GLP-1 drug failed. The company has been losing market share to Eli Lilly.

A competitive drug market strongly encourages companies to best their rivals by developing the next generation of life-saving therapies.

Pfizer offers value with a strong dividend, Metsera obesity expansion, PADCEV/Keytruda approval, and an oncology pipeline.

Share on PinterestNovo Nordisk has announced the cessation of the Evoke trials, looking at whether GLP-1 drugs could help ...

Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without insurance. The drugmaker said Monday that it has started selling higher doses ...

President implored Republicans to make a better case for how much prices are easing in America ahead of next year's mid-term ...

If you're a growth-oriented investor looking for a no-brainer stock to buy with a rock-solid balance sheet and a track record ...

For the first time, an acceptable end to this war is in sight Guardiola apologises for cameraman confrontation: ‘I’m ashamed’ ...

U.S. stocks rallied over the trading week, shortened by the Thanksgiving holiday and a reduced trading session on Friday. The S&P 500 was up around 4% during the week, while the Dow rose a similar ...